M. Harel

Blood RNA Sequencing Indicates Upregulated BATF2 and LY6E and Downregulated ISG15 and MT2A Expression in Children with Autism Spectrum Disorder

D. Gurwitz, N. Shomron, A. Scheck, 2022, International journal of molecular sciences.

Blood RNA Sequencing Confirms Upregulated BATF2 and FCGR1A Expression in Children with Autism Spectrum Disorder

D. Gurwitz, N. Shomron, R. Frye, 2021 .

A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ

A. Aran, H. Cassuto, M. Harel, 2022, Biomedicines.

Cannabinoid treatment for autism: a proof-of-concept randomized trial

F. Castellanos, A. Aran, H. Cassuto, 2021, Molecular Autism.

Lower circulating endocannabinoid levels in children with autism spectrum disorder

J. Tam, A. Aran, S. Tepper, 2019, Molecular Autism.

Mediators of Placebo Response to Cannabinoid Treatment in Children with Autism Spectrum Disorder

A. Aran, M. Harel, Dalit Cayam-Rand, 2023, Journal of clinical medicine.